Auto Amazon Links: No products found. Blocked by captcha.
Laura Marston, a 45-year-old from Derbyshire, found hope in the form of an immunotherapy drug after facing a dire diagnosis of advanced tongue cancer six years ago. This breakthrough treatment has shown promise in extending the lives of hundreds of thousands of people with advanced head and neck cancer, marking a significant advancement in the field.
The traditional methods of treating head and neck cancers have seen little change in the past two decades, with more than half of those diagnosed with advanced forms succumbing to the disease within five years. Laura’s story sheds light on the challenges faced by patients dealing with this difficult-to-treat cancer and the transformative impact that immunotherapy can have on their prognosis.
Participating in an international study that explored new avenues of combating head and neck cancer, Laura received the immunotherapy drug pembrolizumab before and after surgery. This approach helped her body learn to recognize and attack cancer cells, potentially preventing a relapse of the disease.
The positive results of the trial, led by experts from the Institute of Cancer Research in London, showcased a doubling in the average length of time patients remained cancer-free, from 2.5 years to five years. The treatment also reduced the risk of cancer returning elsewhere in the body by 10% after three years. This innovative approach has the potential to revolutionize the way advanced head and neck cancers are managed and treated
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found. Blocked by captcha.